Natural bio-drugs as matrix metalloproteinase inhibitors: New perspectives on the horizon?

Recent Patents on Anti-Cancer Drug Discovery

Volumn 1, Issue 1, 2006, Pages 91-103

  Mannello, Ferdinando ^a  

^a UNIVERSITY OF URBINO   (Italy)

Author keywords

Biodrugs; Cancer; Clinical Trials; Gelatinases; Matrix Metalloproteinases; Natural Compounds; Nutraceuticals; Protease Inhibitors; Therapeutic strategies

Indexed keywords

BIOLOGICAL PRODUCT; MATRIX METALLOPROTEINASE; PROTEINASE INHIBITOR;

ANIMAL; DISEASE COURSE; DRUG ANTAGONISM; HUMAN; NEOPLASM; PATENT; PATHOLOGY; REVIEW;

ANIMALS; BIOLOGICAL PRODUCTS; DISEASE PROGRESSION; HUMANS; MATRIX METALLOPROTEINASES; NEOPLASMS; PATENTS AS TOPIC; PROTEASE INHIBITORS;

EID: 34047252538     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489206775246421     Document Type: Review

References (102)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samueis A, Ward E, Feuer EJ and Thun MJ. Cancer statistics, 2004. CA Cancer J Clin 2004; 54: 8-29.
2. Armstrong WB, Taylor TH, Meyskens FL. Can a marker be a surrogate for development of cancer, and would we know it if it exists? Recent Results Cancer Res 2005; 166: 99-112.
3. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000; 18: 1135-1149.
4. Agnantis NJ, Goussia AC, Batistatou A, Stefanou D. Tumor markers in cancer patients. An update of their prognostic significance. In vivo 2004; 18: 481-488.
5. Mannello F, Tonti G, Papa S. Matrix Metalloproteinase Inhibitors as Targets of Anticancer Therapeutics. Curr Cancer Drug Targets 2005; 5: 285-298.
6. Vu TH, Werb Z. Matrix metalloproteinases: effectors of development and normal physiology. Genes and Development 2000; 14: 2123-2133.
7. Bode W, Maskos K. Matrix Metalloproteinase Protocols. New Jersey, Humana Press 2001; 45-77.
8. Stamenkovic I. Extracellulat matrix remodelling: the role of matrix metalloproteinases. J Pathol 2003; 200: 448-464.
9. Sternlicht MD, Werb Z. How matrix metalloproteinase regulate cell behavior. Annu Rev Cell Dev Biol 2001; 17: 463-516.
10. Mannello F, Gazzanelli G. Tissue inhibitors of metalloproteinases and programmed cell death: conundrums, controversies and potential implications. Apoptosis 2001; 6: 479-482.
11. Gazzanelli G, Luchetti F, Burattini S, Mannello F, Falcieri E, Papa S. Matrix metalloproteinases expression in HL60 promyelocytic leukemia cells during apoptosis. Apoptosis 2000; 5: 165-172.
12. Mannello F, Luchetti F, Falcieri E, Papa S. Multiple roles of matrix metalloproteinases during apoptosis. Apoptosis 2005; 10: 19-24.
13. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Cancer 2002; 2: 163-176.
14. McCawley LJ, Matrisian LM. Matrix metalloproteinases: they're not just for matrix anymore! Curr Opin Cell Biol 2001; 13: 534-540.
15. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-364.
16. Xu J, Rodriguez D, Petieclere E, et al. Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J Cell Biol 2001; 154: 1069-1080.
17. Cornelius L, Nehring LC, Harding E, et al. Matrix metalloproteinases generate angiostatin: effects on neovascularization. J Immunol 1998; 88: 801-810.
18. Ferreras M, Felbor U, Lenhard T, Olsen BR, Delaisse J. Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett 2000; 486: 247-251.
19. Sheu BC, Hsu SM, Ho HN, Lien HC, Huang SC, Lin RH. A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res 2001; 61: 237-242.
20. Overall CM, McQuibban GA, Clark-Lewis I. Discovery of chemokine subtrates for matrix metalloproteinases by exosite scanning: a new tool for degradomics. Biol Chem 2002; 383: 1059-66.
21. Mott JD, Werb Z. Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cancer Biol 2004; 16: 558-564.
22. Lynch CC and Matrisian LM. Matrix metalloproteinases in tumor-host cell communication. Differentiation 2002; 70: 561-573.
23. Vihnen P, Kähäri VM. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 2002; 99: 157-166.
24. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM and Sharie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980; 284: 67-68.
25. Kuittinen O, Soini Y and Turpeenniemi-Hujanen T. Diverse role of MMP-2 and MMP-9 in the clinicopathological behaviour of Hodgkin's lymphoma. Eur J Haematol 2002; 69: 205-212.
26. Kuitten O, Savolainen Er, Koistinen P, et al. Gelatinase A and B (MMP-2, MMP-9) in leukaemia: MMP-2may indicate a good prognosis ai AML. Anticancer Res 1999; 19: 4395-400.
27. Nikkola J, Vihinen P, Vlaykova T. High collagenase-1 expression correlates to favourable chemoimmunotherapy response in human metastatic melanoma. Melanoma Res 2001; 11: 157-66.
28. Scorilas A, Karameris A, Arnogiannaki N, et al. Overexpression of matrix-metalloprotemase-9 m human breast cancer: a potential favourable indicator in node-negative patients. Br J Cancer 2001; 84:1488-1496.
29. Brinckerhoff CE, Matrisian LM. Matrix metalloproteinases: a tail of a frog that became a prince. Mol Cell Biol 2002; 3: 207-214.
30. Mitsiades N, Poulaki V, Mitsiades CS, Anderson KC. Induction of tumour cell apoptosis by matrix metalloproteinase inhibitors: new tricks from a (not so) old drug. Expert Opin Invest Drugs 2001; 10: 1075-1084.
31. Overall C, Lopez-Otìn C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Cancer 2002; 2: 657-672.
32. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002; 295: 2387-2392.
33. Whittaker M, Floyd CD, Brown P, Gearing JH. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem Rev 1999; 99: 2735-2776.
34. Cho J, Kim Y. Sharks: a potential source of antiangiogenic factors and tumor treatments. Mar Biotechnol 2002; 4: 521-5.
35. Dupont, E., Lachance, Y., Lessard, Y., Auger, S.: US20010001041A1 (2001).
36. Gingras D, Renaud A, Mousseau N, Beaulieu E, Kachra Z, Beliveau R. Matrix proteinase inhibition by AE-941, a multifunctional antiangiogenic compound. Anticancer Res 2001; 21: 145-55.
37. Boivin D, Gendron S, Beaulieu E, Gingras D, Bèliveau R. The antiangiogenic agent Neovastat (AE-941) induces endothelial cell apoptosis. Mol Cancer Ther 2002; 1: 795-802.
38. Falardeau P, Champagne P, Poyet P, Hariton C, Dupont E. Neovastat, a natutally occuring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol 2001; 28: 620-5.
39. Weber MH, Lee J, Orr FW. The effect of Neivastat (AE-941) on an experimental metastatic bone tumor model. Int J Oncol 2002; 20: 299-303.
40. Latreille J, Batist G, Laberge F, et al. Phase I/II trial of the safety and efficacy of AE-941 (Neovastat) in the treatment of non-smallcell lung cancer. Clin Lung Cancer 2003; 4: 231-6.
41. Bukowski RM. AE-941, a multifunctional antiangiogenic compound: trials in renal cell carcinoma. Expert Opin Invest Drugs 2003; 12: 1403-11.
42. Gingras D, Boivin D, Deckers C, Gendron S, Barthomeuf C, Beliveau R. Neovastat-a novel antiangiogenic drug for cancer therapy. Anticancer Drugs 2003; 14: 91-96.
43. Dixon RA, Ferreira D. Genistein. Phytochem 2002; 60: 205-211.
44. Lamartiniere CA. Protection against breast cancer with genistein: a component of soy. Am J Clin Nutr 2000; 71: 1705. S-1707S.
45. Lee HP, Gourley L, Duffy SW, Esteve J, Lee J, Day NE. Dietary effects on breast-cancer risk in Singapore. Lancet 1991; 337: 1197-1200.
46. Fritz WA, Coward L, Wang J, Lamartiniere CA. Dietary genistein: perinatal mammary cancerprevention, bioavailability and toxicity testing in the rats. Carcinogenesis 1998; 19: 2151-2158.
47. Shao ZM, Wu J, Shen ZZ, Barsky SH. Genistein exibits both constitutive and EGF-stimulated invasion in ER-negative human breast carcinoma cell lines. Anticancer Res 1998; 18: 1435-9.
48. Kousidou OC, Mitropoulou TN, Roussidis AE, Kletsas D, Theocharis AD, Karamanos NK. Genistein suppresses the invasive potential of human breast cancer cells through transcriptional regulation of metalloproteinases and their tissue inhibitors. Int J Oncol 2005; 26: 1101-9.
49. Shao ZM, Wu J, Shen ZZ, Barsky SH. Genistein exerts multiple suppressive effects on human breast carcinoma cells. Cancer Res 1998; 58: 4851-7.
50. Yanagihara K, Ito A, Toge T, Numoto M. Antiproliferative effects of isoflavones on human cancer cell lines established from the gastrointestinal tract. Cancer Res 1993; 53: 5815-5821.
51. Liu H, Yu GY. Antimetastatic effects of genistein on salivary adenoid cystic carcinoma in vivo. Zhonghua Kou Qiang Yi Xue Za Zhi 2004; 39: 373-5.
52. Yan C, Han R. Effects of genistein o invasion and matrix metalloproteinase activities of HT1080 human fibrosarcoma cells. Chin Med Sci 1999; 14: 129-33.
53. Huang X, Chen S, Xu L, et al. Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human prostate epithelial cells. Cancer Res 2005; 65: 3470-8.
54. Li Y, Che M, Bhagat S, et al. Regulation of gene expression and inhibition of experimental prostate cancer bone metastasis by dietary genistein. Neoplasia 2004; 6: 354-63. [55] Yano, A., Ogawa, K., Yoshida, T., et al.: JP2000080035A2 (2000).
55. Yano, A., Ogawa, K., Yoshida, T., et al.: JP2000080035A2 (2000).
56. Rooprai HK, Kandanearatchi A, Maidment SL, et al. Evaluation of the effects of swainsonine, captopril, tangeretin and nobiletin on the biological behaviour of brain tumour cells in vitro. Neuropothol Appl Neurobiol 2001; 27: 29-39.
57. Kawabata K, Murakami A, Ohigashi H. Nobiletin, A citrus flavonoid, down-regulates matrix metalloproteinase-7 (matrilysin) expression in HT-29 human colorectal cancer cells. Biosci Biotechnol Biochem 2005; 69: 307-14.
58. Minagawa A, Otani Y, Kubota T, et al. The citrus flavonoid, nobiletin, inhibits peritoneal dissemination of human gastric carcinoma in SCID mice. Jpn J Cancer Res 2001; 92: 1322-8.
59. Miyata Y, Sato T, Yano M, Ito A. Activation of protein kinase C betaII/epsilon-c-jun NH2-terminal kinase pathway and inhibition of mitogen-activated protein/extracellular signal-regulated kinase 1/2 phosphorylation in antitumor invasive activity induced by the polymethoxy flavonoid, nobiletin. Mol Cancer Ther 2004; 3: 839-47.
60. Ko CH, Shen SC, Lee TJ, Chen YC. Myricetin inhibits matrix metalloproteinase e protein expression and enzyme activity in colorectal carcinoma cells. Mol Cancer Ther 2005; 4: 281-90.
61. Lin JK, Lin-Shiau SY. Mechanisms of cancer chemoprevention by curcumin. Proc Natl Sci Counc 2001; 25: 59-66.
62. Duvoix A, Blasius R, Delhalle S, et al. Chemopreventive and therapeutic effects of curcumin. Cancer Lett 2005; 223: 181-190.
63. Inomata, S., Suzuki, Y., Okazaki, T.: JP2001139466A2 (2001).
64. Huang MT, Lou YR, Xie JG, et al. Effects of dietary curcumin and dibenzoylmethane on formation of 7,12 dimithylbenzaanthracene-induced mammary tumors and lymphomas/leukemias in Sencar mice. Carcinogenesis 1998; 19: 1697-1700.
65. Samaha HS, Kelloff V, Steele V, Rao CV, Reddy BS. Modulation of apoptosis by sulindac, curcumin, phenylethyl-3-methylcaffeate, and 6-phenylhexyl isothiocyanate: apoptotic index as a biomarker in colon cancer chemoprevention and promotio. Cancer Res 1997; 57: 1301-1305.
66. Verna SP, Salamone E, Goldin B. Curcumin and genistein, plant natural products, show synergistic inhibitory effects on the growth of human breast cancer MCF-7 cells induced by estrogenic pesticides. Biochem Biophys Res Commun 1997; 233: 692-696.
67. Menon LG, Kuttan R, Kuttan G. Anti-metastatic activity of curcumin and catechin. Cancer Lett 1999; 141: 159-165.
68. Cheng Y, Li HL, Wang HF, et al. Inibition of nicotine-DNA adduct formation in mice by six dietary constituents. Food Chem Toxicol 2003; 41: 1045-50.
69. Banerji A, Chakrabarti J, Mitra A, Chatterjee A. Effects of curcumin on gelatinase A/MMP-2) activity in B16F10 melanoma cells. Cancer Lett 2004; 211: 235-42.
70. Liang-In L, Yuh-Fen K, Ya-Chen Ko, Jen-Kun L. Curcumin inhibits SK-Hep-1 hepatocellular carcinoma cell invasion in vitro and suppresses matrix metalloproteinase-9 secretion. Oncol 1998; 55: 349-353.
71. Di GH, Li HC, Shen ZZ, Shao ZM. Analysis of anti-proliferation of curcumin on human breast cancer cells and its mechanism. Zhonghua Yi Xue Za Zhi 2003; 83: 1764-8.
72. Chen HW, Yu SL, Chen JW, et al. Anti. invasive gene expression profile of curcumin in lung adenocarcinoma based on a high throughput microarray analysys. Mol Pharmacology 2004; 65: 99-110.
73. Huang MT, Lysz T, Ferraro T, Abidi TF, Laskin JD, Conney AH. Inhibitory effects of curcumin in vivo lipoxygenase and cyclooxygenase activities in mouse epidermis. Cancer Res 1991; 51: 813-819.
74. Huang MT, Ma W, Yen P, et al. Inhibitory effects of topical application of low doses of curcumin on TPA-induced tumor promotion and oxidized DNA bases in mouse epidermis. Carcinogenesis 1997; 18: 83-88.
75. Subramanian M, Sreejayan Rao MNA, Devasagyam TPA, Singh BB. Diminution of single oxygen-induced DNA-damage by curcumin and relkated antioxidants. Mutat Res 1994; 311: 249-255.
76. Choi MA, Kim SH, Chung WY, Hwang JK, Park KK. Xanthorrizol, a natural sesquiterpenoid from Curcuma xanthorrhiza, has an anti-metastatic potential in experimental mouse lung metastasis model. Biochem Biophys Res Commun 2005; 326: 210-217.
77. Lakka SS, Jasti SL, Gondi C, et al. Downregulation of MMP-9 in ERK-mutated stable transfectants inhibits glioma invasion in vitro. Oncogene 2002; 21: 5601-5608.
78. Yang CS, Wang ZY. Tea and cancer. J Natl Cancer Res Inst 1993; 85: 1038-1049.
79. Akisawa, T., Yahara, M., Hashimoto, F., et al.: JP2000226329A2 (2000).
80. Nakachi K, Suemasu K, Suga K, Takeo T, Imai K, Higashi Y. Influence of drinking tea on breast cancer malignanciy among Japanese patients. Jpn Cancer Res 1998; 89: 254-261.
81. Inoue M, Tajima K, Hirose K, et al. Tea and coffee consumption and the risk of digestive tract cancers: data from a comparative case-referent study in Japan. Cancer Causes Control 1998; 9: 209-216.
82. Liu Q, Wang Y, Crist KA, et al. Effect of green tea on p53 mutation distribution in ultraviolet B radiation-induced mouse skin tumors. Carcinogenesis 1998; 19: 1257-1262.
83. Jankun J, Selman SH, Swiercz R. Why drinking green tea could prevent cancer. Nature 1997; 387: 561.
84. Roy M, Chakrabarty S, Sinha D, Bhattacharky RK, Siddiqi M. Anticlastogenic, antigenotoxic and apoptotic activity of epigallocatechin gallate: a green tea polyphenol. Mutat Res 2003; 523-524: 33-41.
85. Bèliveau R, Gingras D. Green tea: prevention and treatment of cancer by nutraceuticals. Lancet 2004; 364:1021-22.
86. Oku N, Matsukawa M, Yamakawa S, et al. Inhibitory effect of greentea polyphenols on membrane-type 1 matrix metalloproteinase, MT1-MMP. Biol Pharm Bull 2003; 26: 1235-8.
87. Yamakawa S, Asai T, Uchida T, Matsukawa M, Akizawa T, Oku N. (-)-Epogallocatechin gallate inhibits membrane-type 1 matrix metalloproteinase, MT1-MMP, and tumor angiogenesis. Cancer Lett 2004; 210: 47-55.
88. Kim M, Murakami A, Kawabata K, Ohigashi H. (-)-Epigallocatechin-3-gallate promotes pro-matrix metalloproteinase-7 production via activation of the JNK1/2 pothway in HT-29 human colorectal cancer cell. Carcinogenesis 2005; (in press, doi: 10.1093/carcin/bgi104).
89. Garbisa S, Sartor L, Biggin S, Salvato B, Benelli R, Albini A. Tumor gelatinases and invasion inhibited by the green tea flavonol epigallocatechin-3-gallate. Cancer 2001; 91: 822-832.
90. Demeule M, Brossard M, Pagé M, Gingras D, Bèliveau R. Matrix metalloproteinase inhibition by green tea catechins. Biochem Biophys Acta 2000; 1478: 51-60.
91. Cheng XW, Kuzuya M, Kanda S. Epigallocatechin-3-gallate binding to MMP-2 inhibits gelatinolytic activity without influencing the attachment to extracellular matrix proteins but enhances MMP-2 binding to TIMP-2. Arch Biochem Biophys 2003; 415: 126-32.
92. Lambert JD, Yang CS. Mechanisms of cancer prevention by Tea constituents. J Nutr 2003; 133: 3262S-3267S.
93. Chung FL, Schwartz J, Herzog CR, Yang YM. Tea and cancer prevention: studies in animals and humans. J Nutr 2003; 133: 3268S-3274S.
94. Huang MT, Xie JG, Wang ZY, et al. Effects of tea, decaffeinated tea, and caffeine on UVB light-induced complete carcinogenesis in SKH-1 mice: demonstration of caffeine as a biologically importany constituent of the. Cancer Res 1997; 57: 2623-2629.
95. Smith DM, Dou QP. Green tea polyphenol epigallocatechin inhibits DNA replication and consequently induces leukemia cell apoptosis. Int J Mol Med 2001; 7: 645-652.
96. Sazuka M, Imazawa H, Shoji Y, Mita T, Isemura M. Inhibition of collagenases from mouse lung carcinoma cells by green tea catechins and black the theaflavins. Biosci Biotechnol Biochem 1997; 61: 1504-1506.
97. Kirszberg C, Esquenazi D, Alviano CS, Rumjanek VM. The effect of a catechin-rich extract of Cocos nucifera on lymphocytes proliferation. Phytother Res 2003; 17: 1054-8.
98. Pervaiz S. Resveratrol: from grapewines to mammalian biology. FASEB J 2003; 17: 1975-1985.
99. Mouson MM, Farmer PB, Gescher A, Steward WP. Innovative agents in cancer prevention. Recent Results Cancer Res 2005; 166: 257-75.
100. Tang LY, Fang S, Bai-He L, Gui-Fang C. Resveratrol inhibits matrix metalloproteinase-9 transcription in U937 cells. Acta Pharmacol Sin 2003; 24: 1167-1171.
101. Woo JH, Lim JH, Kim YH, et al. Resveratrol inhibits phorbol myristate acetate-induced matrix metalloproteinase-9 expression by inhibiting JNK and PKC delta signal transduction. Oncogene 2004; 23: 1845-53.
102. Sea UK, Lee YJ, Kim JK, et al. Large-scale effective screening of Korean medicinal plants for inhibitory activity on matrix metalloproteinase-9. J Ethnopharmacol 2005; 97: 101-6.